Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

100.98
-1.9084-1.85%
Volume:334.25K
Turnover:33.89M
Market Cap:4.99B
PE:-17.50
High:103.92
Open:102.43
Low:99.98
Close:102.89
Loading ...

Axsome Therapeutics Resolves Sunosi Patent Case With Hikma

MT Newswires Live
·
05 Mar

Axsome Therapeutics Inc - Hikma to Sell Generic Sunosi From Sept 2040 IF Pediatric Exclusivity Granted

THOMSON REUTERS
·
05 Mar

Axsome Therapeutics Settles Sunosi® (Solriamfetol) Patent Litigation With Hikma Pharmaceuticals USA

THOMSON REUTERS
·
05 Mar

Axsome Therapeutics Inc - Co and Hikma to Submit Settlement Agreement for FTC and DOJ Review

THOMSON REUTERS
·
05 Mar

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA

GlobeNewswire
·
05 Mar

Axsome Therapeutics (AXSM) Gets a Buy from Mizuho Securities

TIPRANKS
·
05 Mar

Axsome Therapeutics: Promising Regulatory Progress and Market Potential Justify Buy Rating

TIPRANKS
·
04 Mar

Axsome Therapeutics’ AXS-05: Promising Regulatory Progress and Strategic Positioning for Market Success

TIPRANKS
·
04 Mar

Axsome Therapeutics Receives FDA Indication in Support of Alzheimer's Drug Submission

MT Newswires Live
·
04 Mar

Axsome Therapeutics Is Maintained at Outperform by Baird

Dow Jones
·
03 Mar

Axsome Therapeutics Announces FDA Pre-Nda Meeting Minutes for Axs-05 in Alzheimer’s Disease Agitation Supporting Nda Submission

THOMSON REUTERS
·
03 Mar

Axsome Therapeutics Inc - to Submit Snda for Axs-05 in Q3 2025

THOMSON REUTERS
·
03 Mar

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission

GlobeNewswire
·
03 Mar

Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025

Insider Monkey
·
02 Mar

Mizuho Raises Price Target on Axsome Therapeutics to $212 From $195, Maintains Outperform Rating

MT Newswires Live
·
28 Feb

Axsome Therapeutics price target raised to $190 from $125 at Morgan Stanley

TIPRANKS
·
27 Feb

Axsome Therapeutics Inc : Mizuho Raises Target Price to $212 From $195

THOMSON REUTERS
·
27 Feb

Positive Outlook for Axsome Therapeutics Driven by Symbravo’s Promising Study Results and Market Potential

TIPRANKS
·
27 Feb

Axsome Therapeutics Is Maintained at Outperform by Mizuho

Dow Jones
·
27 Feb

Axsome Therapeutics price target raised to $212 from $195 at Mizuho

TIPRANKS
·
26 Feb